ClinicalTrials.gg
Not yet recruitingNCT07598084Updated Jun 9, 2026

Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement

An observational study in Breast Neoplasms, Artificial Intelligence (AI) and Magnetic Resonance Imaging (MRI), sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Peking University People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
12,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by Peking University People's Hospital — 17 open to participants now, 18 under way, none of them phase 3. Breast Neoplasms · Peking University People's Hospital.

Planned enrollment
Largest of 15
12,000 · median 200
Started
2026
with 6 others
Observational
15 of 32
4 open now
Primary completion
2026-12
later than 7 of 17 live
Registered
30th of 32
by date

Among the 32 studies in Breast Neoplasms by Peking University People's Hospital, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2026, is one of 15 observational ones, reaches primary completion later than 7 of the 17 other live ones, and was the 30th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 32 studies in Breast Neoplasms by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Peking University People's Hospital, or all of them as a file.
02

Study summary

This study is conducted under the ethics-approved project titled "Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI''.The goal of this observational study is to develop an integrated breast MRI system that uses diffusion-weighted imaging (DWI) to create synthetic contrast-enhanced images. This system aims to diagnose and screen for breast cancer without the need for contrast agents, while using a generated risk score to perform imaging-based triage and risk stratification.

Participants will include people aged 18 and older who require a breast MRI either for evaluation of a suspicious finding or for high-risk screening.

This study seeks to answer two main questions:

  • Can synthetic contrast-enhanced images generated from DWI match real contrast-enhanced images in their ability to distinguish benign from malignant breast lesions?
  • Can the risk score derived from DWI-based synthetic images enable imaging-level risk stratification, allowing people at lower risk to avoid contrast agent injection? Researchers will compare the quality of synthetic images against real contrast-enhanced images and will recruit radiologists to assess how well these images perform for diagnostic and screening tasks. MRI data from participants undergoing breast MRI will be used to train, validate, and test this integrated system.
Read the detailed description

We selected "other" in Time Perspective. This study will retrospectively collect MRI data from patients who underwent breast MRI at multiple centers between 2014 and 2024. We will also prospectively enroll MRI data from multiple centers for testing to assess the model's robustness.

03

Conditions studied

  • Breast Neoplasms
  • Artificial Intelligence (AI)
  • Magnetic Resonance Imaging (MRI)
  • Diffusion Magnetic Resonance Imaging
  • Deep Learning

Browse trials for

Keywords

  • Breast
  • Magnetic Resonance Imaging
  • Artificial Intelligence
  • Deep learning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants who underwent breast MR examinations at five institutions from 2014 to 2024 were enrolled. A test cohort prospectively collected at Peking University People's Hospital Health Examination Center, was enrolled to assess the robustness of the model.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Complete breast MRI data;
  2. Negative pathology results or negative follow-up examinations for at least 12 months for non-cancer cases;
  3. Positive biopsy results that meet the requirements for the pathological subtype of cancer for cancer cases;
  4. Original data that can be used to verify clinical status, including radiological and pathological reports;

Exclusion criteria

Exclusion Criteria:

  1. Partial mastectomy or puncture on the diseased side of the breast prior to breast MRI examination;
  2. Poor image quality;
  3. Implants in the affected breast;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
12,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Training cohort

    Participants were retrospectively collected from Peking university people's hospital. All participants have completed the MRI examination and have available images for evaluation.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

  • External test cohort A

    Participants were retrospectively collected from Center A. All participants have completed the MRI examination and have available images for evaluation. All enrolled data will be used for the model testing.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

  • External test cohort B

    Participants were retrospectively collected from center B. All participants have completed the MRI examination and have available images for evaluation. All enrolled data will be used for the model testing.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

  • External test cohort C

    Participants were retrospectively collected from center C. All participants have completed the MRI examination and have available images for evaluation. All enrolled data will be used for the model testing.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

  • External test cohort D

    Participants were retrospectively collected from center D. All participants have completed the MRI examination and have available images for evaluation. All enrolled data will be used for the model testing.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

  • External test cohort E

    Participants were retrospectively collected from center E. All participants have completed the MRI examination and have available images for evaluation. All enrolled data will be used for the model testing.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

  • External test cohort F

    Participants were prospectively enrolled from Center F. All participants will undergo MRI examination and have available images for evaluation. All enrolled data will be used for the model testing.

  • External test cohort G

    Participants were prospectively enrolled from Peking University People's Hospital. All participants will undergo MRI examination and have images available for evaluation. All enrolled data will be used for the model testing.

    Diagnostic Test: Non-contrast breast MRI diagnostic model

Interventions

  • Diagnostic testNon-contrast breast MRI diagnostic model

    An integrated AI model capable of generating synthetic contrast-enhanced images and distinguishing between benign and malignant lesions, as well as performing risk stratification

06

What researchers measure

Primary outcomes

  1. MRI examination

    A multi-parameter contrast-enhanced breast MRI examination was performed, including fat-suppressed T2-weighted imaging, diffusion-weighted imaging, dynamic contrast-enhanced sequences, and fat-suppressed T1-weighted imaging.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Wang P, Wang H, Nie P, Dang Y, Liu R, Qu M, Wang J, Mu G, Jia T, Shang L, Zhu K, Feng J, Chen B. Enabling AI-Generated Content for Gadolinium-Free Contrast-Enhanced Breast Magnetic Resonance Imaging. J Magn Reson Imaging. 2025 Mar;61(3):1232-1243. doi: 10.1002/jmri.29528. Epub 2024 Jul 25. PubMed 39052258 ↗
  • Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY. Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer. Radiology. 2023 Mar;306(3):e239004. doi: 10.1148/radiol.239004. No abstract available. PubMed 36803003 ↗
  • Youn I, Biswas D, Hippe DS, Winter AM, Kazerouni AS, Javid SH, Lee JM, Rahbar H, Partridge SC. Diagnostic Performance of Point-of-Care Apparent Diffusion Coefficient Measures to Reduce Biopsy in Breast Lesions at MRI: Clinical Validation. Radiology. 2024 Feb;310(2):e232313. doi: 10.1148/radiol.232313. PubMed 38349238 ↗
  • Witowski J, Heacock L, Reig B, Kang SK, Lewin A, Pysarenko K, Patel S, Samreen N, Rudnicki W, Luczynska E, Popiela T, Moy L, Geras KJ. Improving breast cancer diagnostics with deep learning for MRI. Sci Transl Med. 2022 Sep 28;14(664):eabo4802. doi: 10.1126/scitranslmed.abo4802. Epub 2022 Sep 28. PubMed 36170446 ↗
  • Gao Y, Zeng S, Xu X, Li H, Yao S, Song K, Li X, Chen L, Tang J, Xing H, Yu Z, Zhang Q, Zeng S, Yi C, Xie H, Xiong X, Cai G, Wang Z, Wu Y, Chi J, Jiao X, Qin Y, Mao X, Chen Y, Jin X, Mo Q, Chen P, Huang Y, Shi Y, Wang J, Zhou Y, Ding S, Zhu S, Liu X, Dong X, Cheng L, Zhu L, Cheng H, Cha L, Hao Y, Jin C, Zhang L, Zhou P, Sun M, Xu Q, Chen K, Gao Z, Zhang X, Ma Y, Liu Y, Xiao L, Xu L, Peng L, Hao Z, Yang M, Wang Y, Ou H, Jia Y, Tian L, Zhang W, Jin P, Tian X, Huang L, Wang Z, Liu J, Fang T, Yan D, Cao H, Ma J, Li X, Zheng X, Lou H, Song C, Li R, Wang S, Li W, Zheng X, Chen J, Li G, Chen R, Xu C, Yu R, Wang J, Xu S, Kong B, Xie X, Ma D, Gao Q. Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study. Lancet Digit Health. 2022 Mar;4(3):e179-e187. doi: 10.1016/S2589-7500(21)00278-8. PubMed 35216752 ↗
  • Amornsiripanitch N, Bickelhaupt S, Shin HJ, Dang M, Rahbar H, Pinker K, Partridge SC. Diffusion-weighted MRI for Unenhanced Breast Cancer Screening. Radiology. 2019 Dec;293(3):504-520. doi: 10.1148/radiol.2019182789. Epub 2019 Oct 8. PubMed 31592734 ↗
  • Baltzer A, Dietzel M, Kaiser CG, Baltzer PA. Combined reading of Contrast Enhanced and Diffusion Weighted Magnetic Resonance Imaging by using a simple sum score. Eur Radiol. 2016 Mar;26(3):884-91. doi: 10.1007/s00330-015-3886-x. Epub 2015 Jun 27. PubMed 26115653 ↗
  • Rahbar H, Zhang Z, Chenevert TL, Romanoff J, Kitsch AE, Hanna LG, Harvey SM, Moy L, DeMartini WB, Dogan B, Yang WT, Wang LC, Joe BN, Oh KY, Neal CH, McDonald ES, Schnall MD, Lehman CD, Comstock CE, Partridge SC. Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702). Clin Cancer Res. 2019 Mar 15;25(6):1756-1765. doi: 10.1158/1078-0432.CCR-18-2967. Epub 2019 Jan 15. PubMed 30647080 ↗
  • Lawson MB, Partridge SC, Hippe DS, Rahbar H, Lam DL, Lee CI, Lowry KP, Scheel JR, Parsian S, Li I, Biswas D, Bryant ML, Lee JM. Comparative Performance of Contrast-enhanced Mammography, Abbreviated Breast MRI, and Standard Breast MRI for Breast Cancer Screening. Radiology. 2023 Aug;308(2):e230576. doi: 10.1148/radiol.230576. PubMed 37581498 ↗
  • Kuhl CK. Abbreviated Breast MRI: State of the Art. Radiology. 2024 Mar;310(3):e221822. doi: 10.1148/radiol.221822. PubMed 38530181 ↗
  • Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Bohm-Velez M, Mahoney MC, Evans WP 3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G; ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012 Apr 4;307(13):1394-404. doi: 10.1001/jama.2012.388. PubMed 22474203 ↗
  • Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S. Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer. Radiology. 2017 May;283(2):361-370. doi: 10.1148/radiol.2016161444. Epub 2017 Feb 21. PubMed 28221097 ↗
  • Mann RM, Kuhl CK, Moy L. Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging. 2019 Aug;50(2):377-390. doi: 10.1002/jmri.26654. Epub 2019 Jan 18. PubMed 30659696 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 6 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 20, 2026
StartEst.
Jun 2026
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07598084
Responsible party
Wang Yi (Professor, Peking University People's Hospital) — Principal investigator
First posted
May 20, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

HAOQUAN CHEN, MD
Contact
CHENHAOQUANSZ@163.COM
+86 010-88325811

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion